导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.58% | 3986/4773 |
| 近一周 | -3.23% | 3840/5458 |
| 近一月 | -2.80% | 1712/5421 |
| 近一季 | 0.83% | 832/5205 |
| 近半年 | -4.94% | 2856/4920 |
| 近一年 | -16.14% | 3800/4361 |
| 近两年 | 30.71% | 2278/2954 |
| 近三年 | 10.80% | 1732/2253 |
| 成立以来 | 23.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.55% 4670/4961 |
8.68% 2562/5312 |
- - |
- - |
| 2025 | 3.89% 3086/4813 |
-6.60% 3373/3635 |
4.28% 809/4076 |
11.16% 3195/4524 |
-4.05% 3381/4813 |
| 2024 | 29.33% 133/3463 |
-4.61% 1717/2808 |
-8.17% 2175/3014 |
41.61% 57/3129 |
4.25% 729/3463 |
| 2023 | 4.10% 245/2656 |
4.18% 1027/2280 |
-2.76% 656/2385 |
7.23% 54/2515 |
-4.17% 899/2655 |
| 2022 | -24.60% 1233/2207 |
-17.87% 1275/1919 |
2.03% 1377/2016 |
-15.24% 1250/2113 |
6.16% 385/2208 |
| 2021 | -1.09% 781/1822 |
-13.83% 1161/1255 |
7.24% 690/1330 |
5.06% 295/1466 |
1.87% 766/1822 |
| 2020 | 22.35% 674/1250 |
-10.47% 782/1028 |
10.37% 771/1067 |
20.96% 45/1164 |
2.36% 994/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 天弘中证全指证券公司ETF联接A VS. 长安沪深300非周期A(740101) |